Global Specific COX-2 Inhibitors Market Research Report 2026

1 Specific COX-2 Inhibitors Market Overview
1.1 Product Definition
1.2 Specific COX-2 Inhibitors by Type
1.2.1 Global Specific COX-2 Inhibitors Market Value by Type: 2025 vs 2032
1.2.2 Etoricoxib
1.2.3 Imrecoxib
1.2.4 Celecoxib
1.2.5 Other
1.3 Specific COX-2 Inhibitors by Application
1.3.1 Global Specific COX-2 Inhibitors Market Value by Application: 2025 vs 2032
1.3.2 Osteoarthritis and Rheumatoid Arthritis
1.3.3 Dysmenorrhea
1.3.4 Relieve Acute Pain
1.3.5 Other
1.4 Global Specific COX-2 Inhibitors Market Size Estimates and Forecasts
1.4.1 Global Specific COX-2 Inhibitors Revenue 2021–2032
1.4.2 Global Specific COX-2 Inhibitors Sales 2021–2032
1.4.3 Global Specific COX-2 Inhibitors Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Specific COX-2 Inhibitors Market Competition by Manufacturers
2.1 Global Specific COX-2 Inhibitors Sales Market Share by Manufacturers (2021–2026)
2.2 Global Specific COX-2 Inhibitors Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Specific COX-2 Inhibitors Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Specific COX-2 Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Specific COX-2 Inhibitors, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Specific COX-2 Inhibitors, Product Types and Applications
2.7 Global Key Manufacturers of Specific COX-2 Inhibitors, Date of Entry into the Industry
2.8 Global Specific COX-2 Inhibitors Market Competitive Situation and Trends
2.8.1 Global Specific COX-2 Inhibitors Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Specific COX-2 Inhibitors Players Market Share by Revenue
2.8.3 Global Specific COX-2 Inhibitors Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Specific COX-2 Inhibitors Market Scenario by Region
3.1 Global Specific COX-2 Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Specific COX-2 Inhibitors Sales by Region: 2021–2032
3.2.1 Global Specific COX-2 Inhibitors Sales by Region: 2021–2026
3.2.2 Global Specific COX-2 Inhibitors Sales by Region: 2027–2032
3.3 Global Specific COX-2 Inhibitors Revenue by Region: 2021–2032
3.3.1 Global Specific COX-2 Inhibitors Revenue by Region: 2021–2026
3.3.2 Global Specific COX-2 Inhibitors Revenue by Region: 2027–2032
3.4 North America Specific COX-2 Inhibitors Market Facts & Figures by Country
3.4.1 North America Specific COX-2 Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Specific COX-2 Inhibitors Sales by Country (2021–2032)
3.4.3 North America Specific COX-2 Inhibitors Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Specific COX-2 Inhibitors Market Facts & Figures by Country
3.5.1 Europe Specific COX-2 Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Specific COX-2 Inhibitors Sales by Country (2021–2032)
3.5.3 Europe Specific COX-2 Inhibitors Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Specific COX-2 Inhibitors Market Facts & Figures by Region
3.6.1 Asia Pacific Specific COX-2 Inhibitors Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Specific COX-2 Inhibitors Sales by Region (2021–2032)
3.6.3 Asia Pacific Specific COX-2 Inhibitors Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Specific COX-2 Inhibitors Market Facts & Figures by Country
3.7.1 Latin America Specific COX-2 Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Specific COX-2 Inhibitors Sales by Country (2021–2032)
3.7.3 Latin America Specific COX-2 Inhibitors Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Specific COX-2 Inhibitors Market Facts & Figures by Country
3.8.1 Middle East and Africa Specific COX-2 Inhibitors Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Specific COX-2 Inhibitors Sales by Country (2021–2032)
3.8.3 Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Specific COX-2 Inhibitors Sales by Type (2021–2032)
4.1.1 Global Specific COX-2 Inhibitors Sales by Type (2021–2026)
4.1.2 Global Specific COX-2 Inhibitors Sales by Type (2027–2032)
4.1.3 Global Specific COX-2 Inhibitors Sales Market Share by Type (2021–2032)
4.2 Global Specific COX-2 Inhibitors Revenue by Type (2021–2032)
4.2.1 Global Specific COX-2 Inhibitors Revenue by Type (2021–2026)
4.2.2 Global Specific COX-2 Inhibitors Revenue by Type (2027–2032)
4.2.3 Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021–2032)
4.3 Global Specific COX-2 Inhibitors Price by Type (2021–2032)
5 Segment by Application
5.1 Global Specific COX-2 Inhibitors Sales by Application (2021–2032)
5.1.1 Global Specific COX-2 Inhibitors Sales by Application (2021–2026)
5.1.2 Global Specific COX-2 Inhibitors Sales by Application (2027–2032)
5.1.3 Global Specific COX-2 Inhibitors Sales Market Share by Application (2021–2032)
5.2 Global Specific COX-2 Inhibitors Revenue by Application (2021–2032)
5.2.1 Global Specific COX-2 Inhibitors Revenue by Application (2021–2026)
5.2.2 Global Specific COX-2 Inhibitors Revenue by Application (2027–2032)
5.2.3 Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021–2032)
5.3 Global Specific COX-2 Inhibitors Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Organon Pharma
6.1.1 Organon Pharma Company Information
6.1.2 Organon Pharma Description and Business Overview
6.1.3 Organon Pharma Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Organon Pharma Specific COX-2 Inhibitors Product Portfolio
6.1.5 Organon Pharma Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Company Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Pfizer Specific COX-2 Inhibitors Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Zentiva
6.3.1 Zentiva Company Information
6.3.2 Zentiva Description and Business Overview
6.3.3 Zentiva Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Zentiva Specific COX-2 Inhibitors Product Portfolio
6.3.5 Zentiva Recent Developments/Updates
6.4 Neopharmed Gentili
6.4.1 Neopharmed Gentili Company Information
6.4.2 Neopharmed Gentili Description and Business Overview
6.4.3 Neopharmed Gentili Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Neopharmed Gentili Specific COX-2 Inhibitors Product Portfolio
6.4.5 Neopharmed Gentili Recent Developments/Updates
6.5 Eskayef Pharmaceuticals
6.5.1 Eskayef Pharmaceuticals Company Information
6.5.2 Eskayef Pharmaceuticals Description and Business Overview
6.5.3 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
6.5.5 Eskayef Pharmaceuticals Recent Developments/Updates
6.6 Zydus
6.6.1 Zydus Company Information
6.6.2 Zydus Description and Business Overview
6.6.3 Zydus Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 Zydus Specific COX-2 Inhibitors Product Portfolio
6.6.5 Zydus Recent Developments/Updates
6.7 Teva
6.7.1 Teva Company Information
6.7.2 Teva Description and Business Overview
6.7.3 Teva Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 Teva Specific COX-2 Inhibitors Product Portfolio
6.7.5 Teva Recent Developments/Updates
6.8 Mylan Pharmaceutical
6.8.1 Mylan Pharmaceutical Company Information
6.8.2 Mylan Pharmaceutical Description and Business Overview
6.8.3 Mylan Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Mylan Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.8.5 Mylan Pharmaceutical Recent Developments/Updates
6.9 Actavis
6.9.1 Actavis Company Information
6.9.2 Actavis Description and Business Overview
6.9.3 Actavis Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Actavis Specific COX-2 Inhibitors Product Portfolio
6.9.5 Actavis Recent Developments/Updates
6.10 Jiangsu Hengrui Pharmaceuticals
6.10.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.10.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.10.3 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product Portfolio
6.10.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.11 Qingdao Baheal Medical
6.11.1 Qingdao Baheal Medical Company Information
6.11.2 Qingdao Baheal Medical Description and Business Overview
6.11.3 Qingdao Baheal Medical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 Qingdao Baheal Medical Specific COX-2 Inhibitors Product Portfolio
6.11.5 Qingdao Baheal Medical Recent Developments/Updates
6.12 Qilu Pharmaceutical
6.12.1 Qilu Pharmaceutical Company Information
6.12.2 Qilu Pharmaceutical Description and Business Overview
6.12.3 Qilu Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.12.4 Qilu Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.12.5 Qilu Pharmaceutical Recent Developments/Updates
6.13 Shanxi Tongda Pharmaceutical
6.13.1 Shanxi Tongda Pharmaceutical Company Information
6.13.2 Shanxi Tongda Pharmaceutical Description and Business Overview
6.13.3 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.13.4 Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.13.5 Shanxi Tongda Pharmaceutical Recent Developments/Updates
6.14 Sichuan Kelun Pharmaceutical
6.14.1 Sichuan Kelun Pharmaceutical Company Information
6.14.2 Sichuan Kelun Pharmaceutical Description and Business Overview
6.14.3 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.14.4 Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.14.5 Sichuan Kelun Pharmaceutical Recent Developments/Updates
6.15 Jiangsu Chiatai Qingjiang Pharmaceutical
6.15.1 Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
6.15.2 Jiangsu Chiatai Qingjiang Pharmaceutical Description and Business Overview
6.15.3 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.15.4 Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.15.5 Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments/Updates
6.16 Beijing Yabao Biological Pharmaceutical
6.16.1 Beijing Yabao Biological Pharmaceutical Company Information
6.16.2 Beijing Yabao Biological Pharmaceutical Description and Business Overview
6.16.3 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales, Revenue, and Gross Margin (2021–2026)
6.16.4 Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product Portfolio
6.16.5 Beijing Yabao Biological Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Specific COX-2 Inhibitors Industry Chain Analysis
7.2 Specific COX-2 Inhibitors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Specific COX-2 Inhibitors Production Mode & Process Analysis
7.4 Specific COX-2 Inhibitors Sales and Marketing
7.4.1 Specific COX-2 Inhibitors Sales Channels
7.4.2 Specific COX-2 Inhibitors Distributors
7.5 Specific COX-2 Inhibitors Customer Analysis
8 Specific COX-2 Inhibitors Market Dynamics
8.1 Specific COX-2 Inhibitors Industry Trends
8.2 Specific COX-2 Inhibitors Market Drivers
8.3 Specific COX-2 Inhibitors Market Challenges
8.4 Specific COX-2 Inhibitors Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Tables
Table 1. Global Specific COX-2 Inhibitors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Specific COX-2 Inhibitors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Specific COX-2 Inhibitors Market Competitive Situation by Manufacturers in 2025
Table 4. Global Specific COX-2 Inhibitors Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Specific COX-2 Inhibitors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Specific COX-2 Inhibitors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Specific COX-2 Inhibitors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Specific COX-2 Inhibitors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Specific COX-2 Inhibitors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Specific COX-2 Inhibitors, Product Types and Applications
Table 12. Global Key Manufacturers of Specific COX-2 Inhibitors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Specific COX-2 Inhibitors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Specific COX-2 Inhibitors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Specific COX-2 Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Specific COX-2 Inhibitors Sales by Region (K Units), 2021–2026
Table 18. Global Specific COX-2 Inhibitors Sales Market Share by Region (2021–2026)
Table 19. Global Specific COX-2 Inhibitors Sales by Region (K Units), 2027–2032
Table 20. Global Specific COX-2 Inhibitors Sales Market Share by Region (2027–2032)
Table 21. Global Specific COX-2 Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 22. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2021–2026)
Table 23. Global Specific COX-2 Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 24. Global Specific COX-2 Inhibitors Revenue Market Share by Region (2027–2032)
Table 25. North America Specific COX-2 Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Specific COX-2 Inhibitors Sales by Country (K Units), 2021–2026
Table 27. North America Specific COX-2 Inhibitors Sales by Country (K Units), 2027–2032
Table 28. North America Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 29. North America Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Specific COX-2 Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Specific COX-2 Inhibitors Sales by Country (K Units), 2021–2026
Table 32. Europe Specific COX-2 Inhibitors Sales by Country (K Units), 2027–2032
Table 33. Europe Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Specific COX-2 Inhibitors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Specific COX-2 Inhibitors Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Specific COX-2 Inhibitors Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Specific COX-2 Inhibitors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Specific COX-2 Inhibitors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Specific COX-2 Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Specific COX-2 Inhibitors Sales by Country (K Units), 2021–2026
Table 42. Latin America Specific COX-2 Inhibitors Sales by Country (K Units), 2027–2032
Table 43. Latin America Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Specific COX-2 Inhibitors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Specific COX-2 Inhibitors Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Specific COX-2 Inhibitors Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Specific COX-2 Inhibitors Revenue by Country (US$ Million), 2027–2032
Table 50. Global Specific COX-2 Inhibitors Sales (K Units) by Type (2021–2026)
Table 51. Global Specific COX-2 Inhibitors Sales (K Units) by Type (2027–2032)
Table 52. Global Specific COX-2 Inhibitors Sales Market Share by Type (2021–2026)
Table 53. Global Specific COX-2 Inhibitors Sales Market Share by Type (2027–2032)
Table 54. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2021–2026)
Table 57. Global Specific COX-2 Inhibitors Revenue Market Share by Type (2027–2032)
Table 58. Global Specific COX-2 Inhibitors Price (US$/Unit) by Type (2021–2026)
Table 59. Global Specific COX-2 Inhibitors Price (US$/Unit) by Type (2027–2032)
Table 60. Global Specific COX-2 Inhibitors Sales (K Units) by Application (2021–2026)
Table 61. Global Specific COX-2 Inhibitors Sales (K Units) by Application (2027–2032)
Table 62. Global Specific COX-2 Inhibitors Sales Market Share by Application (2021–2026)
Table 63. Global Specific COX-2 Inhibitors Sales Market Share by Application (2027–2032)
Table 64. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Specific COX-2 Inhibitors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2021–2026)
Table 67. Global Specific COX-2 Inhibitors Revenue Market Share by Application (2027–2032)
Table 68. Global Specific COX-2 Inhibitors Price (US$/Unit) by Application (2021–2026)
Table 69. Global Specific COX-2 Inhibitors Price (US$/Unit) by Application (2027–2032)
Table 70. Organon Pharma Company Information
Table 71. Organon Pharma Description and Business Overview
Table 72. Organon Pharma Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Organon Pharma Specific COX-2 Inhibitors Product
Table 74. Organon Pharma Recent Developments/Updates
Table 75. Pfizer Company Information
Table 76. Pfizer Description and Business Overview
Table 77. Pfizer Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Pfizer Specific COX-2 Inhibitors Product
Table 79. Pfizer Recent Developments/Updates
Table 80. Zentiva Company Information
Table 81. Zentiva Description and Business Overview
Table 82. Zentiva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. Zentiva Specific COX-2 Inhibitors Product
Table 84. Zentiva Recent Developments/Updates
Table 85. Neopharmed Gentili Company Information
Table 86. Neopharmed Gentili Description and Business Overview
Table 87. Neopharmed Gentili Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Neopharmed Gentili Specific COX-2 Inhibitors Product
Table 89. Neopharmed Gentili Recent Developments/Updates
Table 90. Eskayef Pharmaceuticals Company Information
Table 91. Eskayef Pharmaceuticals Description and Business Overview
Table 92. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. Eskayef Pharmaceuticals Specific COX-2 Inhibitors Product
Table 94. Eskayef Pharmaceuticals Recent Developments/Updates
Table 95. Zydus Company Information
Table 96. Zydus Description and Business Overview
Table 97. Zydus Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. Zydus Specific COX-2 Inhibitors Product
Table 99. Zydus Recent Developments/Updates
Table 100. Teva Company Information
Table 101. Teva Description and Business Overview
Table 102. Teva Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. Teva Specific COX-2 Inhibitors Product
Table 104. Teva Recent Developments/Updates
Table 105. Mylan Pharmaceutical Company Information
Table 106. Mylan Pharmaceutical Description and Business Overview
Table 107. Mylan Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Mylan Pharmaceutical Specific COX-2 Inhibitors Product
Table 109. Mylan Pharmaceutical Recent Developments/Updates
Table 110. Actavis Company Information
Table 111. Actavis Description and Business Overview
Table 112. Actavis Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Actavis Specific COX-2 Inhibitors Product
Table 114. Actavis Recent Developments/Updates
Table 115. Jiangsu Hengrui Pharmaceuticals Company Information
Table 116. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
Table 117. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Jiangsu Hengrui Pharmaceuticals Specific COX-2 Inhibitors Product
Table 119. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
Table 120. Qingdao Baheal Medical Company Information
Table 121. Qingdao Baheal Medical Description and Business Overview
Table 122. Qingdao Baheal Medical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. Qingdao Baheal Medical Specific COX-2 Inhibitors Product
Table 124. Qingdao Baheal Medical Recent Developments/Updates
Table 125. Qilu Pharmaceutical Company Information
Table 126. Qilu Pharmaceutical Description and Business Overview
Table 127. Qilu Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 128. Qilu Pharmaceutical Specific COX-2 Inhibitors Product
Table 129. Qilu Pharmaceutical Recent Developments/Updates
Table 130. Shanxi Tongda Pharmaceutical Company Information
Table 131. Shanxi Tongda Pharmaceutical Description and Business Overview
Table 132. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 133. Shanxi Tongda Pharmaceutical Specific COX-2 Inhibitors Product
Table 134. Shanxi Tongda Pharmaceutical Recent Developments/Updates
Table 135. Sichuan Kelun Pharmaceutical Company Information
Table 136. Sichuan Kelun Pharmaceutical Description and Business Overview
Table 137. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 138. Sichuan Kelun Pharmaceutical Specific COX-2 Inhibitors Product
Table 139. Sichuan Kelun Pharmaceutical Recent Developments/Updates
Table 140. Jiangsu Chiatai Qingjiang Pharmaceutical Company Information
Table 141. Jiangsu Chiatai Qingjiang Pharmaceutical Description and Business Overview
Table 142. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 143. Jiangsu Chiatai Qingjiang Pharmaceutical Specific COX-2 Inhibitors Product
Table 144. Jiangsu Chiatai Qingjiang Pharmaceutical Recent Developments/Updates
Table 145. Beijing Yabao Biological Pharmaceutical Company Information
Table 146. Beijing Yabao Biological Pharmaceutical Description and Business Overview
Table 147. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 148. Beijing Yabao Biological Pharmaceutical Specific COX-2 Inhibitors Product
Table 149. Beijing Yabao Biological Pharmaceutical Recent Developments/Updates
Table 150. Key Raw Materials Lists
Table 151. Raw Materials Key Suppliers Lists
Table 152. Specific COX-2 Inhibitors Distributors List
Table 153. Specific COX-2 Inhibitors Customers List
Table 154. Specific COX-2 Inhibitors Market Trends
Table 155. Specific COX-2 Inhibitors Market Drivers
Table 156. Specific COX-2 Inhibitors Market Challenges
Table 157. Specific COX-2 Inhibitors Market Restraints
Table 158. Research Programs/Design for This Report
Table 159. Key Data Information from Secondary Sources
Table 160. Key Data Information from Primary Sources
Table 161. Authors List of This Report


List of Figures
Figure 1. Product Picture of Specific COX-2 Inhibitors
Figure 2. Global Specific COX-2 Inhibitors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Specific COX-2 Inhibitors Market Share by Type: 2025 & 2032
Figure 4. Etoricoxib Product Picture
Figure 5. Imrecoxib Product Picture
Figure 6. Celecoxib Product Picture
Figure 7. Other Product Picture
Figure 8. Global Specific COX-2 Inhibitors Market Value by Application (US$ Million), 2021–2032
Figure 9. Global Specific COX-2 Inhibitors Market Share by Application: 2025 & 2032
Figure 10. Osteoarthritis and Rheumatoid Arthritis
Figure 11. Dysmenorrhea
Figure 12. Relieve Acute Pain
Figure 13. Other
Figure 14. Global Specific COX-2 Inhibitors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 15. Global Specific COX-2 Inhibitors Market Size (US$ Million), 2021–2032
Figure 16. Global Specific COX-2 Inhibitors Sales (K Units), 2021–2032
Figure 17. Global Specific COX-2 Inhibitors Average Price (US$/Unit), 2021–2032
Figure 18. Specific COX-2 Inhibitors Report Years Considered
Figure 19. Specific COX-2 Inhibitors Sales Share by Manufacturers in 2025
Figure 20. Global Specific COX-2 Inhibitors Revenue Share by Manufacturers in 2025
Figure 21. Top 5 and Top 10 Global Specific COX-2 Inhibitors Players: Market Share by Revenue in Specific COX-2 Inhibitors in 2025
Figure 22. Specific COX-2 Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 23. Global Specific COX-2 Inhibitors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 24. North America Specific COX-2 Inhibitors Sales Market Share by Country (2021–2032)
Figure 25. North America Specific COX-2 Inhibitors Revenue Market Share by Country (2021–2032)
Figure 26. United States Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 27. Canada Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. Europe Specific COX-2 Inhibitors Sales Market Share by Country (2021–2032)
Figure 29. Europe Specific COX-2 Inhibitors Revenue Market Share by Country (2021–2032)
Figure 30. Germany Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. France Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. U.K. Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 33. Italy Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 34. Russia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Asia Pacific Specific COX-2 Inhibitors Sales Market Share by Region (2021–2032)
Figure 36. Asia Pacific Specific COX-2 Inhibitors Revenue Market Share by Region (2021–2032)
Figure 37. China Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Japan Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. South Korea Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. India Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Australia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 42. China Taiwan Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 43. Southeast Asia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Latin America Specific COX-2 Inhibitors Sales Market Share by Country (2021–2032)
Figure 45. Latin America Specific COX-2 Inhibitors Revenue Market Share by Country (2021–2032)
Figure 46. Mexico Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Brazil Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 48. Argentina Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 49. Colombia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Middle East and Africa Specific COX-2 Inhibitors Sales Market Share by Country (2021–2032)
Figure 51. Middle East and Africa Specific COX-2 Inhibitors Revenue Market Share by Country (2021–2032)
Figure 52. Turkey Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 53. Saudi Arabia Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 54. UAE Specific COX-2 Inhibitors Revenue Growth Rate (US$ Million), 2021–2032
Figure 55. Global Sales Market Share of Specific COX-2 Inhibitors by Type (2021–2032)
Figure 56. Global Revenue Market Share of Specific COX-2 Inhibitors by Type (2021–2032)
Figure 57. Global Specific COX-2 Inhibitors Price (US$/Unit) by Type (2021–2032)
Figure 58. Global Sales Market Share of Specific COX-2 Inhibitors by Application (2021–2032)
Figure 59. Global Revenue Market Share of Specific COX-2 Inhibitors by Application (2021–2032)
Figure 60. Global Specific COX-2 Inhibitors Price (US$/Unit) by Application (2021–2032)
Figure 61. Specific COX-2 Inhibitors Value Chain
Figure 62. Channels of Distribution (Direct Vs Distribution)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit